Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumorsSergio Pedraza‐Arévalo, Justo P. Castaño, Emilia Alors‐Pérez et al.|Translational research|2022Cited by 22
Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST <sub>5</sub> ) in pituitary and pancreatic neuroendocrine tumorsSergio Pedraza‐Arévalo, Justo P. Castaño, Eva Venegas‐Moreno et al.|Molecular Oncology|2021Cited by 14
Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus responseEmilia Alors‐Pérez, Justo P. Castaño, Sergio Pedraza‐Arévalo et al.|Molecular Therapy — Nucleic Acids|2023Cited by 13
Spliceosomic dysregulation unveils <i>NOVA1</i> as an actionable therapeutic target in pancreatic neuroendocrine tumorsSergio Pedraza‐Arévalo, Justo P. Castaño, Emilia Alors‐Pérez et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 0
Alternative splicing dysregulation in pancreatic neuroendocrine tumors: splicing factor CELF4 is upregulated in PanNETs and is associated with aggressivenessRicardo Blázquez‐Encinas, Justo P. Castaño, Sergio Pedraza‐Arévalo et al.|Pancreatology|2020Cited by 0